- Topic
11k Popularity
14k Popularity
43k Popularity
5k Popularity
702 Popularity
115k Popularity
28k Popularity
26k Popularity
7k Popularity
15k Popularity
- Pin
- 🔥 Gate Square #Gate Alpha Third Points Carnival# Trading Sharing Event - 5 Days Left!
Share Alpha trading screenshots with #Gate Alpha Trading Share# to split $100!
🎁 10 lucky users * 10 USDT each
📅 July 4, 4:00 – July 20, 16:00 UTC+8
Gate Alpha 3rd Points Carnival Issue 10 is in full swing!
Trade and post for double the chances to win!
Learn more: https://www.gate.com/campaigns/1522alpha?pid=KOL&ch=5J261cdf
- 📢 Gate has released its latest Proof of Reserves report!
As of July 11, 2025:
💰 Total reserves reached $10.504 billion
📈 Reserve ratio stands at 126.03%
✅ Covers over 350 types of user assets
🔼 Surplus reserves increased 10.66% to $2.17 billion
Committed to transparency and user fund security.
📎 Learn more: https://www.gate.com/proof-of-reserves
- 📢 Gate Square #Creator Campaign Phase 1# is now live – support the launch of the PUMP token sale!
The viral Solana-based project Pump.Fun ($PUMP) is now live on Gate for public sale!
Join the Gate Square Creator Campaign, unleash your content power, and earn rewards!
📅 Campaign Period: July 11, 18:00 – July 15, 22:00 (UTC+8)
🎁 Total Prize Pool: $500 token rewards
✅ Event 1: Create & Post – Win Content Rewards
📅 Timeframe: July 12, 22:00 – July 15, 22:00 (UTC+8)
📌 How to Join:
Post original content about the PUMP project on Gate Square:
Minimum 100 words
Include hashtags: #Creator Campaign
- 🎉 [Gate 30 Million Milestone] Share Your Gate Moment & Win Exclusive Gifts!
Gate has surpassed 30M users worldwide — not just a number, but a journey we've built together.
Remember the thrill of opening your first account, or the Gate merch that’s been part of your daily life?
📸 Join the #MyGateMoment# campaign!
Share your story on Gate Square, and embrace the next 30 million together!
✅ How to Participate:
1️⃣ Post a photo or video with Gate elements
2️⃣ Add #MyGateMoment# and share your story, wishes, or thoughts
3️⃣ Share your post on Twitter (X) — top 10 views will get extra rewards!
👉
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world's largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.